The abstract is read at the publisher; the summary is JClub's.
GLP-1 receptor agonist use and misuse are being assessed in a US cross-sectional sample of people with eating disorders, quantifying how common these behaviors are.
- Why it matters: Eating disorders can involve medication misuse, but the prevalence of GLP-1 receptor agonist use and misuse in this population in the US is not well characterized.
- What they did: The study used a cross-sectional design to evaluate prevalence of GLP-1 receptor agonist use and misuse among people with eating disorders in the US.
- The result: The findings provide prevalence estimates that can inform how GLP-1 receptor agonists are being used and misused in this US eating-disorder population.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.